Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.
Biotech 2050 Podcast
Claim This Podcastby Biotech 2050
4.9(134 reviews)
260 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
60
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality80
Social0
YouTube0
Engagement99
Podcast Overview
Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.
Language
🇺🇲
Publishing Since
10/1/2019
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
60
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality80
Social0
YouTube0
Engagement99
8
Excellent Areas
2
Good Performance
9
Growth Opportunities
excellent
Episode Length
31 minutes
Performing excellently!
good
Publishing Consistency
Every 9 days
Recommendations available
Unlock the full report to see detailed tips
poor
Episode Thumbnails
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Biotech 2050 Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
May 13, 2026
Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision
Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically rich conversation on leadership, commercialization, and the future of neuropsychiatry. From starting as a pharmacist in the UK to pivoting from R&D into commercial leadership at Johnson & Johnson, rising through Bristol Myers Squibb, and ultimately stepping into her first biotech CEO role at Acadia, Catherine shares how storytelling became the throughline of her career—transforming science into physician trust, investor conviction, and enterprise vision. In this episode, Catherine opens up about the personal family experiences with neurodegenerative disease that made Acadia’s focus on CNS and rare disease feel like her “Goldilocks opportunity.” She offers a candid look at the realities of being a first-time CEO, managing investor ecosystems, building the right C-suite, balancing billion-dollar commercial execution with high-risk R&D, and navigating the emotional stakes of developing therapies for Parkinson’s disease psychosis, Alzheimer’s disease psychosis, Rett syndrome, and beyond. Rahul and Catherine also explore the seismic shifts reshaping biotech—from AI-powered commercialization and patient services to policy advocacy through BIO, FDA modernization, and the strategic pressures facing CNS innovation. This episode is both a masterclass in biotech leadership and a powerful reminder that the best CEOs don’t just run companies—they tell stories that move science, markets, and patients forward. Biography: Ms. Owen Adams joined Acadia as Chief Executive Officer and as a member of our Board of Directors in September 2024. Ms. Owen Adams has over 25 years of executive level experience in the pharmaceutical industry. Prior to joining Acadia, Ms. Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb (BMS), where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology. Previously, Ms. Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS, where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS’s merger with Celgene. Prior to her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson (J&J), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Ms. Owen Adams began her career in R&D and manufacturing at AstraZeneca. Ms. Owen Adams currently serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms. Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a non-profit organization. Ms. Owen Adams earned a BSc. in Pharmacy from the University of Manchester, becoming a qualified pharmacist and member of the Royal Pharmaceutical Society (MRPhS).
April 16, 2026
Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership
Alok Tayi interviews Dr. Barry Quart, CEO of Connect Biopharma, discussing asthma innovation, biotech leadership, and the future of inflammatory disease treatment.
March 6, 2026
Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics
Host Alok Tayi interviews Adial Pharmaceuticals CEO Cary Claiborne about a new genetic therapy for alcohol addiction, offering a precision-medicine approach to reduce cravings.
260 total episodes available with 1 transcripts
Recent guests on Biotech 2050 Podcast
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Barry Quart
Guest
Cary Claiborne
Guest
Sheila Gujrathi
Guest
Fred Aslan
Guest
Michelle Werner
Guest
Brian Hilberdink
Guest
Johan Luthman
Guest
Christophe Bourdon
Guest
Matt Gline
Guest
Jay Hartenbach
Guest
John Lepore
Guest
John Lepore MD
Guest
Similar Podcasts
Discover related shows you might enjoy
The Readout Loud
STAT
Business Of Biotech
Ben Comer
Biotech Hangout
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
BioCentury This Week
BioCentury
The Long Run with Luke Timmerman
Timmerman Report
The BioCentury Show
BioCentury
Hard Fork
The New York Times
Nature Podcast
Springer Nature Limited
Matter of Opinion
New York Times Opinion
The Ezra Klein Show
New York Times Opinion
Motley Fool Money
The Motley Fool
The Daily
The New York Times
No Priors: Artificial Intelligence | Machine Learning | Technology | Startups
Conviction
The Long View
Morningstar, Christine Benz - Director of Personal Finance and Retirement Planning, Ben Johnson - Head of Client Solutions, Amy Arnott - Portfolio Strategist
This Week in Startups
Jason Calacanis
Deep-dive analytics for Biotech 2050 Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Biotech 2050 Podcast?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.